Access to the human papillomavirus vaccine is lowest in states with the lowest income levels, where cervical cancer death rates are highest and girls and women stand to benefit most from vaccination, according to a study in the Lancet, USA Today reports (Szabo, USA Today, 3/18). The study focused on Gardasil, which was the only HPV vaccine on the market at the time of the study...